| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Walterspiel JN | |
| Schaad UB | |||
| Burkhardt JE | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | quinolones | Q426549 |
| P304 | page(s) | 1196-1204 | |
| P577 | publication date | 1997-11-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Quinolone arthropathy in animals versus children | |
| P478 | volume | 25 |
| Q34318461 | 4-(3-Carb-oxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-7-quinol-yl)-1-methyl-piper-azin-ium picrate |
| Q44436666 | A case of Mycoplasma hominis meningo-encephalitis in a full-term infant: rapid recovery after start of treatment with ciprofloxacin |
| Q34248416 | A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections |
| Q38837774 | Adverse effects of oral second-line antituberculosis drugs in children. |
| Q57021160 | An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+ |
| Q34533896 | Anthrax: safe treatment for children |
| Q37283490 | Antibiotic prophylaxis in the management of vesicoureteral reflux |
| Q28255152 | Antimicrobial safety: focus on fluoroquinolones |
| Q38963213 | Childhood tuberculosis--problems ahead |
| Q40552783 | Ciprofloxacin after clinical failure of beta-lactam antibiotics in children with salmonellosis |
| Q43668865 | Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: does the benefit outweigh the risk? |
| Q33756171 | Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. |
| Q56969094 | Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis |
| Q33985235 | Clinical use of fluoroquinolones in children |
| Q40368730 | Colonic diverticular abscess presenting as chronic diarrhea: a case report. |
| Q34437719 | Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics |
| Q28146268 | Comparative tolerability of the newer fluoroquinolone antibacterials |
| Q44005875 | Complicated nosocomial pneumonia due to Legionella pneumophila in an immunocompromised child |
| Q33268601 | Diminished ciprofloxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats |
| Q34724032 | Do fluoroquinolones commonly cause arthropathy in children? |
| Q92759827 | Drug-induced Pseudochondritis: A Case Report |
| Q53799188 | Effects of nalidixic acid on hamster knee cartilage morphology and synovial fluid composition. |
| Q28084595 | Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections |
| Q34408447 | Fluoroquinolone adverse effects and drug interactions |
| Q38386834 | Fluoroquinolones for the treatment of tuberculosis in children. |
| Q33770091 | Fluoroquinolones in paediatrics |
| Q73976052 | Fluoroquinolones in paediatrics |
| Q35211282 | Fluoroquinolones in paediatrics: a risk for the patient or for the community? |
| Q35167433 | Fluoroquinolones, tuberculosis, and resistance |
| Q81679199 | Gatifloxacin Therapy in Otitis Media in Children |
| Q34301619 | High prevalence of antimicrobial resistance among Shigella isolates in the United States tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. |
| Q34301493 | In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model |
| Q45155638 | Instant 99mTc-ciprofloxacin scintigraphy for the diagnosis of osteomyelitis in the diabetic foot |
| Q34182294 | Levofloxacin |
| Q35917230 | Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'. |
| Q30080000 | Lung infections associated with cystic fibrosis |
| Q37988983 | Management of children exposed to multidrug-resistant Mycobacterium tuberculosis |
| Q37730293 | Management of multidrug-resistant tuberculosis: an update |
| Q42275450 | Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience. |
| Q92325220 | Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs |
| Q34136663 | Nontyphoidal salmonellosis |
| Q36290751 | Options for treating resistant Shigella species infections in children |
| Q37961280 | Paediatric use of second-line anti-tuberculosis agents: a review |
| Q33698908 | Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015. |
| Q30322975 | Pharmacokinetic factors in the modern drug treatment of tuberculosis. |
| Q36075800 | Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. |
| Q33856763 | Pharmacokinetics of gatifloxacin in infants and children |
| Q90099770 | Population Dynamics of Salmonella enterica within Beef Cattle Cohorts Followed from Single-Dose Metaphylactic Antibiotic Treatment until Slaughter |
| Q42603473 | Population pharmacokinetics of ciprofloxacin in pediatric patients |
| Q33978259 | Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice |
| Q34191394 | Provider and health care system response to a bioterrorist attack. |
| Q35554389 | Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management |
| Q57923254 | Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis |
| Q35193051 | Rapid and sensitive determination of levofloxacin in microsamples of human plasma by high-performance liquid chromatography and its application in a pharmacokinetic study. |
| Q92289597 | Real-world safety evaluation of musculoskeletal adverse events associated with Korean pediatric fluoroquinolone use: a nationwide longitudinal retrospective cohort study |
| Q28085210 | Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children |
| Q38728987 | Safety Concerns Surrounding Quinolone Use in Children |
| Q38353565 | Safety and tolerability profile of second-line anti-tuberculosis medications |
| Q35194456 | Safety of fluoroquinolones in paediatrics. |
| Q77323810 | Safety of quinolones administration in children? |
| Q39530082 | Severe acute polyarthritis in a child after high doses of moxifloxacin |
| Q45087885 | State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis |
| Q39755545 | Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States |
| Q38563985 | The Risk of Musculoskeletal Adverse Events With Fluoroquinolones in Children: What Is the Verdict Now? |
| Q40636919 | The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? |
| Q34334345 | The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model |
| Q33583442 | The place of quinolones in paediatric anti-infective therapy |
| Q34391558 | The role of antibiotics in the treatment of infectious diarrhea |
| Q34005865 | The safety profile of the fluoroquinolones. |
| Q36516533 | Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia |
Search more.